Veterinary Vaccines Market by Type, Technology, Route of Administration, End User - Global Forecast to 2031

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN VETERINARY VACCINES MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3.1 VETERINARY VACCINES MARKET OVERVIEW
3.2 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY AND END USER
3.3 GEOGRAPHIC SNAPSHOT OF VETERINARY VACCINES MARKET

4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Increase in companion animal population and pet ownership
4.2.1.2 Increasing incidence of infectious and zoonotic diseases
4.2.1.3 Favorable initiatives by government agencies and animal health organizations
4.2.1.4 Growing demand for animal-derived food products
4.2.1.5 Increasing pet insurance penetration and animal health expenditure
4.2.2 RESTRAINTS
4.2.2.1 High cost of veterinary vaccine development, manufacturing, and cold-chain distribution
4.2.3 OPPORTUNITIES
4.2.3.1 Advancements in vaccine technologies and strategic collaborations
4.2.3.2 Untapped opportunities in emerging livestock and companion animal markets
4.2.4 CHALLENGES
4.2.4.1 Limited awareness, training gaps, and shortage of veterinary professionals in low-income countries
4.2.4.2 Stringent regulatory pathways and complex approval frameworks
4.3 UNMET NEEDS & WHITE SPACES
4.3.1 UNMET NEEDS IN VETERINARY VACCINES MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 STRATEGIC MOVES IN VETERINARY VACCINES MARKET

5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL ANIMAL HEALTH INDUSTRY
5.2.4 TRENDS IN GLOBAL VETERINARY BIOLOGICS INDUSTRY
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 MANUFACTURERS
5.5.2 END USERS
5.5.3 REGULATORY BODIES
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2023-2025
5.6.2 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY ROUTE OF ADMINISTRATION, 2023-2025
5.6.3 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY END USER, 2023-2025
5.6.4 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY REGION, 2023-2025
5.7 TRADE ANALYSIS
5.7.1 IMPORT DATA (HS CODE 3002)
5.7.2 EXPORT DATA FOR (HS CODE 3002)
5.8 REIMBURSEMENT SCENARIO
5.9 KEY CONFERENCES & EVENTS, 2026-2027
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.11 INVESTMENT & FUNDING SCENARIO
5.12 CASE STUDY ANALYSIS
5.13 IMPACT OF 2025 US TARIFFS ON VETERINARY VACCINES MARKET
5.13.1 INTRODUCTION
5.13.2 KEY TARIFF RATES
5.13.3 PRICE IMPACT ANALYSIS
5.13.4 IMPACT ON COUNTRY/REGION
5.13.5 IMPACT ON END-USE SEGMENTS
5.13.5.1 Veterinary Hospitals
5.13.5.2 Veterinary Clinics
5.13.5.3 Other End Users (Veterinary Research Organizations, Government Vaccination Centers)

6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Recombinant DNA technology
6.1.1.2 mRNA-based vaccines
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Vaccine adjuvant technology
6.1.2.2 Needle-free & microneedle technology
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Genome editing technology
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.2.1 NEAR TERM (2025-2027)
6.2.2 MID TERM (2028-2030)
6.2.3 LONG TERM (2030+)
6.3 PATENT ANALYSIS
6.3.1 JURISDICTION & TOP APPLICANT ANALYSIS
6.4 FUTURE APPLICATIONS
6.4.1 AI-ENABLED & DATA-DRIVEN PROCEDURE OPTIMIZATION
6.4.2 PERSONALIZED & PRECISION VACCINATION
6.4.3 CONNECTED ANIMAL HEALTH ECOSYSTEMS & DIGITAL INTEGRATION
6.5 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET
6.5.1 INTRODUCTION
6.5.2 MARKET POTENTIAL OF AI IN VETERINARY VACCINES
6.5.3 AI USE CASES
6.5.3.1 Vaccine Discovery and Antigen Identification
6.5.3.2 Disease Surveillance and Outbreak Prediction
6.5.3.3 Vaccine Formulation and Manufacturing Optimization
6.5.3.4 Precision Vaccination and Herd Health Management
6.5.3.5 Regulatory Intelligence and Scientific Workflow Automation
6.5.4 KEY COMPANIES IMPLEMENTING AI

7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY ANALYSIS
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Rest of the world
7.1.3 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 RECYCLED & ECO-FRIENDLY MATERIALS FOR VETERINARY VACCINES
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8.1 KEY STAKEHOLDERS & BUYING CRITERIA
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.1.2 BUYING CRITERIA
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2.1 DECISION-MAKING PROCESS
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2.4 MARKET PROFITABILITY

9.1 INTRODUCTION
9.2 LIVESTOCK VACCINES
9.2.1 BOVINE VACCINES
9.2.1.1 Increasing demand for meat and milk to drive market
9.2.1.2 Global volume analysis of bovine vaccines, 2024-2031 (thousand units)
9.2.2 SMALL RUMINANT VACCINES
9.2.2.1 Increased livestock population and favorable government initiatives to propel market growth
9.2.2.2 Global volume analysis of small ruminant vaccines, 2024-2031 (thousand units)
9.3 PORCINE VACCINES
9.3.1 GROWING AWARENESS ABOUT ANIMAL VACCINATION TO SUPPORT MARKET GROWTH
9.3.1.1 Global volume analysis of porcine vaccines, 2024-2031 (thousand units)
9.4 POULTRY VACCINES
9.4.1 HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH
9.4.1.1 Global volume analysis of poultry vaccines, 2024-2031 (thousand units)
9.5 COMPANION ANIMAL VACCINES
9.5.1 CANINE VACCINES
9.5.1.1 Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth
9.5.1.2 Global volume analysis of Canine vaccines, 2024-2031(thousand units)
9.5.2 FELINE VACCINES
9.5.2.1 Rising adoption of cats and growing need for better veterinary care to boost market growth
9.5.2.2 Global volume analysis of feline vaccines, 2024-2031 (thousand units)
9.6 AQUACULTURE VACCINES
9.6.1 INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO FUEL MARKET GROWTH
9.6.1.1 Global volume analysis of aquaculture vaccines, 2024-2031 (thousand units)
9.7 OTHER VETERINARY VACCINES

10.1 INTRODUCTION
10.2 LIVESTOCK DISEASES
10.2.1 BOVINE DISEASES
10.2.1.1 Increasing government support to aid the market growth
10.2.2 SMALL RUMINANT DISEASES
10.2.2.1 Growing ruminant vaccines demand to propel the market growth
10.3 PORCINE DISEASES
10.3.1 PORCINE DISEASES TO ACCOUNT FOR LARGEST SHARE
10.4 POULTRY DISEASES
10.4.1 GROWING GOVERNMENT PROGRAMME TO CONTROL POULTRY DISEASES
10.5 COMPANION ANIMAL DISEASES
10.5.1 CANINE DISEASES
10.5.1.1 Innovative canine vaccine development to
10.5.2 FELINE DISEASES
10.5.2.1 Feline disease segment to grow at highest CAGR during forecast period
10.6 AQUACULTURE DISEASES
10.6.1 GROWING FOCUS ON DEVELOPING AQUACULTURE VACCINES
10.7 OTHER DISEASES

11.1 INTRODUCTION
11.2 LIVE ATTENUATED VACCINES
11.2.1 EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO SUPPORT MARKET GROWTH
11.3 INACTIVATED VACCINES
11.3.1 NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING PATHOGENS TO DRIVE MARKET
11.4 TOXOID VACCINES
11.4.1 TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS
11.5 RECOMBINANT VACCINES
11.5.1 BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION
11.6 OTHER VACCINE TECHNOLOGIES

12.1 INTRODUCTION
12.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION
12.2.1 EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH
12.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION
12.3.1 BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH
12.4 ORAL ROUTE OF ADMINISTRATION
12.4.1 COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH
12.5 INTRANASAL/SPRAY ROUTE OF ADMINISTRATION
12.5.1 COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION
12.6 INTRAOCULAR ROUTE OF ADMINISTRATION
12.6.1 SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH
12.7 OTHER ROUTES OF ADMINISTRATION

13.1 INTRODUCTION
13.2 VETERINARY HOSPITALS
13.2.1 GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET
13.3 VETERINARY CLINICS
13.3.1 RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO SPUR MARKET GROWTH
13.4 OTHER END USERS

14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 NORTH AMERICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024-2031(THOUSAND UNITS)
14.2.3 US
14.2.3.1 US to dominate North American veterinary vaccines market during forecast period
14.2.4 CANADA
14.2.4.1 Rising pet ownership and increasing chicken consumption to drive demand for veterinary vaccines
14.3 EUROPE
14.3.1 EUROPE: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024-2031(THOUSAND UNITS)
14.3.2 MACROECONOMIC OUTLOOK FOR EUROPE
14.3.3 GERMANY
14.3.3.1 Increased poultry consumption and high pet healthcare expenditure to drive market
14.3.4 UK
14.3.4.1 Rising adoption of pets to augment market growth
14.3.5 FRANCE
14.3.5.1 Rising companion animal and livestock population to boost market growth
14.3.6 ITALY
14.3.6.1 Better availability of pet products through large-scale outlets to augment market growth
14.3.7 SPAIN
14.3.7.1 Increase in veterinary practices and willingness to spend on animal healthcare to drive market
14.3.8 NETHERLANDS
14.3.8.1 High-density livestock production and strong biosecurity standards to drive market growth
14.3.9 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2 ASIA PACIFIC: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024-2031(THOUSAND UNITS)
14.4.3 CHINA
14.4.3.1 Increasing companion animal population and growing incidence of zoonotic diseases to drive market
14.4.4 JAPAN
14.4.4.1 High consumption of animal-derived products and increased pet health expenditure to propel market growth
14.4.5 INDIA
14.4.5.1 Growth in poultry industry and high demand for dairy products to augment market growth
14.4.6 AUSTRALIA
14.4.6.1 Increase in per capita income and rise in meat consumption to aid market growth
14.4.7 SOUTH KOREA
14.4.7.1 High demand for animal protein and favorable government subsidies for meat production to spur market growth
14.4.8 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 LATIN AMERICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024-2031(THOUSAND UNITS)
14.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.3 BRAZIL
14.5.3.1 Well-established livestock industry to promote market growth
14.5.4 MEXICO
14.5.4.1 Focus on pork and poultry meat production to fuel market growth
14.5.5 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024-2031(THOUSAND UNITS)
14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
14.6.3 GCC COUNTRIES
14.6.3.1 Kingdom of Saudi Arabia
14.6.3.1.1 Favorable government initiatives for better animal health infrastructure to propel market growth
14.6.3.2 UAE
14.6.3.2.1 Favorable government initiatives to safeguard national livestock population and support sustainable agriculture
14.6.3.3 Rest of GCC countries
14.6.4 REST OF MIDDLE EAST & AFRICA

15.1 INTRODUCTION
15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2024-2026
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY VACCINES MARKET
15.3 REVENUE ANALYSIS, 2023-2025
15.4 MARKET SHARE ANALYSIS, 2025
15.4.1 GLOBAL MARKET SHARE ANALYSIS (2025)
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Type footprint
15.5.5.3 Disease footprint
15.5.5.4 Technology footprint
15.5.5.5 Route of administration footprint
15.5.5.6 Region footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of key startups/SMEs
15.7 COMPANY VALUATION & FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
15.9.4 OTHER DEVELOPMENTS

16.1 KEY PLAYERS
16.1.1 MERCK & CO., INC.
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches & approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 The Analyst's View
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 ZOETIS SERVICES LLC
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product approvals
16.1.2.3.2 Deals
16.1.2.3.3 Expansions
16.1.2.3.4 Other developments
16.1.2.4 The Analyst's View
16.1.2.4.1 Right to win
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches
16.1.3.3.2 Expansions
16.1.3.4 The Analyst's View
16.1.3.4.1 Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 ELANCO
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product approvals
16.1.4.3.2 Deals
16.1.4.4 The Analyst's View
16.1.4.4.1 Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses & competitive threats
16.1.5 VIRBAC
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product launches
16.1.5.3.2 Deals
16.1.5.3.3 Expansions
16.1.5.4 The Analyst's View
16.1.5.4.1 Right to win
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses & competitive threats
16.1.6 CEVA
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product launches
16.1.6.3.2 Expansions
16.1.7 PHIBRO ANIMAL HEALTH CORPORATION
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.8 HESTER BIOSCIENCES LIMITED
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Product approvals
16.1.8.3.2 Deals
16.1.9 NEOGEN CORPORATION
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Deals
16.1.10 HIPRA
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product launches
16.1.10.3.2 Deals
16.1.11 BIOGÉNESIS BAGÓ
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Deals
16.1.11.3.2 Expansions
16.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.13 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.2.1 Other developments
16.1.14 JINYU BIOTECHNOLOGY CO., LTD.
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product approvals
16.1.15 VAXXINOVA INTERNATIONAL B.V.
16.1.15.1 Business overview
16.1.15.2 Products offered
16.1.15.3 Recent developments
16.1.15.3.1 Product approvals
16.1.15.3.2 Deals
16.1.15.3.3 Expansions
16.2 OTHER COMPANIES
16.2.1 ENDOVAC ANIMAL HEALTH REBRAND CA
16.2.2 BRILLIANT BIO PHARMA PRIVATE LIMITED
16.2.3 APTIMMUNE
16.2.4 INDIAN IMMUNOLOGICALS LTD.
16.2.5 TORIGEN
16.2.6 INTAS PHARMACEUTICALS LTD.
16.2.7 OUROFINO S.A
16.2.8 BIOVAC LTD.
16.2.9 LABORATOIRE LCV
16.2.10 KYORITSU SEIYAKU CORPORATION

17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.1.1 Key data from secondary sources
17.1.2 PRIMARY DATA
17.1.2.1 Key data from primary sources
17.1.2.2 Key industry insights
17.1.2.3 Breakdown of primary interviews
17.1.2.4 Key industry insights
17.2 MARKET SIZE ESTIMATION
17.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH
17.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
17.2.3 APPROACH 3: BOTTOM APPROACH
17.2.4 APPROACH 4: TOP-DOWN
17.2.5 BASE NUMBER CALCULATION
17.2.6 COMPANY PRESENTATIONS
17.2.7 PRIMARY INTERVIEWS
17.2.8 APPROACH 5: VOLUME ESTIMATION
17.2.9 APPROACH 6: DEMAND-SIDE
17.3 MARKET BREAKDOWN AND DATA TRIANGULATION
17.4 MARKET SHARE ASSESSMENT
17.5 RESEARCH ASSUMPTIONS
17.5.1 STUDY ASSUMPTIONS
17.5.2 GROWTH RATE ASSUMPTIONS
17.6 RISK ASSESSMENT
17.6.1 RESEARCH LIMITATIONS

18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: THE SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS

TABLE 1 STANDARD CURRENCY CONVERSION RATES
TABLE 2 GLOBAL MEAT MARKET INDICATORS, 2024 VS. 2025
TABLE 3 PAST AND PROJECTED TRENDS IN CONSUMPTION OF MEAT AND MILK (DEVELOPED VS. EMERGING MARKETS)
TABLE 4 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
TABLE 5 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
TABLE 6 KEY COST AND OPERATIONAL CHALLENGES ASSOCIATED WITH VACCINE DEVELOPMENT
TABLE 7 VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 8 GDP CHANGE, BY KEY COUNTRY, 2021-2030 (USD BILLION)
TABLE 9 LIST OF KEY VETERINARY VACCINE MANUFACTURERS
TABLE 10 LIST OF KEY END USERS
TABLE 11 LIST OF KEY REGULATORY BODIES
TABLE 12 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2023-2025 (USD)
TABLE 13 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY ROUTE OF ADMINISTRATION, 2023-2025 (USD)
TABLE 14 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY END USER, 2023-2025 (USD)
TABLE 15 AVERAGE SELLING PRICE TREND OF CANINE VACCINES, BY REGION, 2023-2025 (USD)
TABLE 16 IMPORT DATA FOR HS CODE 3002-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 17 EXPORT DATA FOR HS CODE 3002-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD THOUSAND)
TABLE 18 VETERINARY VACCINES MARKET: MAJOR CONFERENCES & EVENTS, 2026-2027
TABLE 19 BOVILIS NASALGEN-C: IMPROVED GROWTH PERFORMANCE AND REDUCED RESPIRATORY DISEASE IN VEAL CALVES
TABLE 20 UNISTRAIN PRRS: ENHANCED PRRS CONTROL AND REDUCED ANTIBIOTIC USAGE IN COMMERCIAL SWINE PRODUCTION
TABLE 21 FAO RABIES VACCINATION CASE STUDY
TABLE 22 RECIPROCAL TARIFF RATES ADJUSTED BY US, 2025
TABLE 23 KEY PRODUCT-RELATED TARIFF
TABLE 24 NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA
TABLE 25 ASIA PACIFIC: IMPACT OF US TARIFFS ON CHINA, JAPAN, AND INDIA
TABLE 26 EUROPE: IMPACT OF US TARIFFS ON GERMANY AND UK
TABLE 27 LATIN AMERICA: IMPACT OF US TARIFFS ON MEXICO
TABLE 28 VETERINARY VACCINES MARKET: KEY PATENTS, 2023-2025
TABLE 29 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 30 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 31 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VETERINARY VACCINES
TABLE 33 KEY BUYING CRITERIA FOR VETERINARY VACCINES, BY END USER
TABLE 34 VETERINARY VACCINES MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 35 VETERINARY VACCINES MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
TABLE 36 VETERINARY VACCINES MARKET: KEY PROFITABILITY DRIVERS
TABLE 37 VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 38 LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 39 LIVESTOCK VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 40 KEY PLAYERS PROVIDING BOVINE VACCINES
TABLE 41 BOVINE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 42 BOVINE VACCINES MARKET, BY REGION, 2024-2031 (THOUSAND UNITS)
TABLE 43 KEY PLAYERS PROVIDING SMALL RUMINANT VACCINES
TABLE 44 SMALL RUMINANT VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 45 SMALL RUMINANT VACCINES MARKET, BY REGION, 2024-2031 (THOUSAND UNITS)
TABLE 46 KEY PLAYERS PROVIDING PORCINE VACCINES
TABLE 47 PORCINE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 48 PORCINE VACCINES MARKET, BY REGION, 2024-2031 (THOUSAND UNITS)
TABLE 49 KEY PLAYERS PROVIDING POULTRY VACCINES
TABLE 50 POULTRY VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 51 POULTRY VACCINES MARKET, BY REGION, 2024-2031 (THOUSAND UNITS)
TABLE 52 COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 53 COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 54 KEY PLAYERS PROVIDING CANINE VACCINES
TABLE 55 CANINE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 56 CANINE VACCINES MARKET, BY REGION, 2024-2031 (THOUSAND UNITS)
TABLE 57 KEY PLAYERS PROVIDING FELINE VACCINES
TABLE 58 FELINE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 59 FELINE VACCINES MARKET, BY REGION, 2024-2031 (THOUSAND UNITS)
TABLE 60 KEY PLAYERS PROVIDING AQUACULTURE VACCINES
TABLE 61 AQUACULTURE VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 62 AQUACULTURE VACCINES MARKET, BY REGION, 2024-2031 (THOUSAND UNITS)
TABLE 63 KEY PLAYERS PROVIDING OTHER COMMERCIAL VETERINARY VACCINES
TABLE 64 OTHER VETERINARY VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 65 VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 66 LIVESTOCK VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 67 LIVESTOCK DISEASES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 68 BOVINE DISEASES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 69 SMALL RUMINANT DISEASES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 70 PORCINE DISEASES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 71 POULTRY DISEASES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 72 COMPANION ANIMAL VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 73 COMPANION ANIMAL DISEASES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 74 CANINE DISEASES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 75 FELINE DISEASES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 76 AQUACULTURE DISEASES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 77 OTHER DISEASES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 78 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 79 LIVE ATTENUATED VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 80 INACTIVATED VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 81 TOXOID VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 82 RECOMBINANT VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 83 OTHER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 84 ROUTES OF ADMINISTRATION FOR MAJOR VETERINARY VACCINES, BY KEY PLAYER
TABLE 85 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 86 COMMERCIALLY AVAILABLE VACCINES WITH SUBCUTANEOUS ROUTE OF ADMINISTRATION
TABLE 87 VETERINARY VACCINES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 88 COMMERCIALLY AVAILABLE VACCINES WITH INTRAMUSCULAR ROUTE OF ADMINISTRATION
TABLE 89 VETERINARY VACCINES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 90 COMMERCIALLY AVAILABLE VACCINES WITH ORAL ROUTE OF ADMINISTRATION
TABLE 91 VETERINARY VACCINES MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 92 COMMERCIALLY AVAILABLE VACCINES WITH INTRANASAL/SPRAY ROUTE OF ADMINISTRATION
TABLE 93 VETERINARY VACCINES MARKET FOR INTRANASAL/SPRAY ROUTE OF ADMINISTRATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 94 COMMERCIALLY AVAILABLE VACCINES WITH INTRAOCULAR ROUTE OF ADMINISTRATION
TABLE 95 VETERINARY VACCINES MARKET FOR INTRAOCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 96 COMMERCIALLY AVAILABLE VACCINES WITH OTHER ROUTES OF ADMINISTRATION
TABLE 97 VETERINARY VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 98 VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 99 VETERINARY HOSPITALS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 100 VETERINARY CLINICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 101 OTHER END USERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 102 VETERINARY VACCINES MARKET, BY REGION, 2024-2031 (USD MILLION)
TABLE 103 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031(THOUSAND UNITS)
TABLE 104 NORTH AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 105 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 106 NORTH AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 107 NORTH AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 108 NORTH AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 109 NORTH AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 110 NORTH AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 111 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 112 NORTH AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 113 NORTH AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 114 US: KEY MACROINDICATORS
TABLE 115 US: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 116 US: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 117 US: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 118 US: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 119 US: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 120 US: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 121 US: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 122 US: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 123 US: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 124 CANADA: KEY MACROINDICATORS
TABLE 125 CANADA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 126 CANADA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 127 CANADA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 128 CANADA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 129 CANADA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 130 CANADA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 131 CANADA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 132 CANADA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 133 CANADA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 134 EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031(THOUSAND UNITS)
TABLE 135 EUROPE: VETERINARY VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 136 EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 137 EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 138 EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 139 EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 140 EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 141 EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 142 EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 143 EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 144 EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 145 GERMANY: KEY MACROINDICATORS
TABLE 146 GERMANY: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 147 GERMANY: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 148 GERMANY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 149 GERMANY: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 150 GERMANY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 151 GERMANY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 152 GERMANY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 153 GERMANY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 154 GERMANY: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 155 UK: KEY MACROINDICATORS
TABLE 156 UK: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 157 UK: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 158 UK: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 159 UK: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 160 UK: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 161 UK: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 162 UK: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 163 UK: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 164 UK: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 165 FRANCE: KEY MACROINDICATORS
TABLE 166 FRANCE: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 167 FRANCE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 168 FRANCE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 169 FRANCE: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 170 FRANCE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 171 FRANCE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 172 FRANCE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 173 FRANCE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 174 FRANCE: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 175 ITALY: KEY MACROINDICATORS
TABLE 176 ITALY: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 177 ITALY: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 178 ITALY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 179 ITALY: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 180 ITALY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 181 ITALY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 182 ITALY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 183 ITALY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 184 ITALY: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 185 SPAIN: KEY MACROINDICATORS
TABLE 186 SPAIN: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 187 SPAIN: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 188 SPAIN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 189 SPAIN: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 190 SPAIN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 191 SPAIN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 192 SPAIN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 193 SPAIN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 194 SPAIN: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 195 NETHERLANDS: KEY MACROINDICATORS
TABLE 196 NETHERLANDS: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 197 NETHERLANDS: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 198 NETHERLANDS: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 199 NETHERLANDS: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 200 NETHERLANDS: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 201 NETHERLANDS: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 202 NETHERLANDS: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 203 NETHERLANDS: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 204 NETHERLANDS: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 205 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 206 REST OF EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 207 REST OF EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 208 REST OF EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 209 REST OF EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 210 REST OF EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 211 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 212 REST OF EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 213 REST OF EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 214 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031(THOUSAND UNITS)
TABLE 215 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 216 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 217 ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 220 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 221 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 222 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 223 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 224 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 225 CHINA: KEY MACROINDICATORS
TABLE 226 CHINA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 227 CHINA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 228 CHINA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 229 CHINA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 230 CHINA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 231 CHINA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 232 CHINA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 233 CHINA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 234 CHINA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 235 JAPAN: KEY MACROINDICATORS
TABLE 236 JAPAN: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 237 JAPAN: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 238 JAPAN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 239 JAPAN: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 240 JAPAN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 241 JAPAN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 242 JAPAN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 243 JAPAN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 244 JAPAN: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 245 INDIA: KEY MACROINDICATORS
TABLE 246 INDIA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 247 INDIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 248 INDIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 249 INDIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 250 INDIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 251 INDIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 252 INDIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 253 INDIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 254 INDIA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 255 AUSTRALIA: KEY MACROINDICATORS
TABLE 256 AUSTRALIA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 257 AUSTRALIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 258 AUSTRALIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 259 AUSTRALIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 260 AUSTRALIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 261 AUSTRALIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 262 AUSTRALIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 263 AUSTRALIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 264 AUSTRALIA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 265 SOUTH KOREA: KEY MACROINDICATORS
TABLE 266 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 267 SOUTH KOREA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 268 SOUTH KOREA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 269 SOUTH KOREA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 270 SOUTH KOREA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 271 SOUTH KOREA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 272 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 273 SOUTH KOREA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 274 SOUTH KOREA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 275 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 276 REST OF ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 277 REST OF ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 278 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 279 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 280 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 281 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 282 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 283 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 284 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031(THOUSAND UNITS)
TABLE 285 LATIN AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 286 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 287 LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 288 LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 289 LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 290 LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 291 LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 292 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 293 LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 294 LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 295 BRAZIL: KEY MACROINDICATORS
TABLE 296 BRAZIL: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 297 BRAZIL: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 298 BRAZIL: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 299 BRAZIL: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 300 BRAZIL: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 301 BRAZIL: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 302 BRAZIL: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 303 BRAZIL: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 304 BRAZIL: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 305 MEXICO: KEY MACROINDICATORS
TABLE 306 MEXICO: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 307 MEXICO: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 308 MEXICO: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 309 MEXICO: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 310 MEXICO: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 311 MEXICO: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 312 MEXICO: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 313 MEXICO: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 314 MEXICO: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 315 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 316 REST OF LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 317 REST OF LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 318 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 319 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 320 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 321 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 322 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 323 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 324 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031(THOUSAND UNITS)
TABLE 325 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
TABLE 326 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 327 MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 328 MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 329 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 330 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 331 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 332 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 333 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 334 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 335 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 336 GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 337 GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 338 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 339 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 340 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 341 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 342 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 343 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 344 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
TABLE 345 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 346 KINGDOM OF SAUDI ARABIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 347 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 348 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 349 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 350 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 351 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 352 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 353 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 354 UNITED ARAB EMIRATES: KEY MACROINDICATORS
TABLE 355 UAE: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 356 UAE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 357 UAE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 358 UAE: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 359 UAE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 360 UAE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 361 UAE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 362 UAE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 363 UAE: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 364 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 365 REST OF GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 366 REST OF GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 367 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 368 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 369 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 370 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 371 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 372 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 373 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 374 REST OF MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 375 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024-2031 (USD MILLION)
TABLE 376 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024-2031 (USD MILLION)
TABLE 377 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 378 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024-2031 (USD MILLION)
TABLE 379 REST OF MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
TABLE 380 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
TABLE 381 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2024-2031 (USD MILLION)
TABLE 382 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN VETERINARY VACCINES MARKET, JANUARY 2023-MAY 2026
TABLE 383 VETERINARY VACCINES MARKET: DEGREE OF COMPETITION
TABLE 384 VETERINARY VACCINES MARKET: TYPE FOOTPRINT
TABLE 385 VETERINARY VACCINES MARKET: DISEASE FOOTPRINT
TABLE 386 VETERINARY VACCINES MARKET: TECHNOLOGY FOOTPRINT
TABLE 387 VETERINARY VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
TABLE 388 VETERINARY VACCINES MARKET: REGION FOOTPRINT
TABLE 389 VETERINARY VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 390 VETERINARY VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
TABLE 391 VETERINARY VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026
TABLE 392 VETERINARY VACCINES MARKET: DEALS, JANUARY 2023-MAY 2026
TABLE 393 VETERINARY VACCINES MARKET: EXPANSIONS, JANUARY 2023-MAY 2026
TABLE 394 VETERINARY VACCINES MARKET: OTHER DEVELOPMENTS, JANUARY 2023-MAY 2026
TABLE 395 MERCK & CO., INC.: COMPANY OVERVIEW
TABLE 396 MERCK & CO., INC.: PRODUCTS OFFERED
TABLE 397 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023 - MAY 2026
TABLE 398 MERCK & CO., INC.: DEALS, JANUARY 2023 - MAY 2026
TABLE 399 MERCK & CO., INC.: EXPANSIONS, JANUARY 2023 - MAY 2026
TABLE 400 ZOETIS SERVICES LLC: COMPANY OVERVIEW
TABLE 401 ZOETIS SERVICES LLC: PRODUCTS OFFERED
TABLE 402 ZOETIS SERVICES LLC: PRODUCT APPROVALS, JANUARY 2023 - MAY 2026
TABLE 403 ZOETIS SERVICES LLC: DEALS, JANUARY 2023 - MAY 2026
TABLE 404 ZOETIS SERVICES LLC: EXPANSIONS, JANUARY 2023-MAY 2026
TABLE 405 ZOETIS SERVICES LLC: OTHER DEVELOPMENTS, JANUARY 2023-MAY 2026
TABLE 406 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
TABLE 407 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
TABLE 408 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT LAUNCHES, JANUARY 2023 - MAY 2026
TABLE 409 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2023-MAY 2026
TABLE 410 ELANCO: COMPANY OVERVIEW
TABLE 411 ELANCO: PRODUCTS OFFERED
TABLE 412 ELANCO: PRODUCT APPROVALS JANUARY 2023 - MAY 2026
TABLE 413 ELANCO: DEALS, JANUARY 2023-MAY 2026
TABLE 414 VIRBAC: COMPANY OVERVIEW
TABLE 415 VIRBAC: PRODUCTS OFFERED
TABLE 416 VIRBAC: PRODUCT LAUNCHES, JANUARY 2023 - MAY 2026
TABLE 417 VIRBAC: DEALS, JANUARY 2023-MAY 2026
TABLE 418 VIRBAC: EXPANSIONS, JANUARY 2023-MAY 2026
TABLE 419 CEVA: COMPANY OVERVIEW
TABLE 420 CEVA: PRODUCTS OFFERED
TABLE 421 CEVA: PRODUCT LAUNCHES: JANUARY 2023 - MAY 2026
TABLE 422 CEVA: EXPANSIONS, JANUARY 2023-MAY 2026
TABLE 423 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY OVERVIEW
TABLE 424 PHIBRO ANIMAL HEALTH CORPORATION: PRODUCTS OFFERED
TABLE 425 HESTER BIOSCIENCES LIMITED: COMPANY OVERVIEW
TABLE 426 HESTER BIOSCIENCES LIMITED: PRODUCTS OFFERED
TABLE 427 HESTER BIOSCIENCES LIMITED: PRODUCT APPROVALS, JANUARY 2023 - MAY 2026
TABLE 428 HESTER BIOSCIENCES LIMITED: DEALS, JANUARY 2023-MAY 2026
TABLE 429 NEOGEN CORPORATION: COMPANY OVERVIEW
TABLE 430 NEOGEN CORPORATION: PRODUCTS OFFERED
TABLE 431 NEOGEN CORPORATION: DEALS, JANUARY 2023-MAY 2026
TABLE 432 HIPRA: COMPANY OVERVIEW
TABLE 433 HIPRA: PRODUCTS OFFERED
TABLE 434 HIPRA: PRODUCT LAUNCHES, JANUARY 2023 - MAY 2026
TABLE 435 HIPRA: DEALS, JANUARY 2023-MAY 2026
TABLE 436 BIOGÉNESIS BAGÓ: COMPANY OVERVIEW
TABLE 437 BIOGÉNESIS BAGÓ: PRODUCTS OFFERED
TABLE 438 BIOGÉNESIS BAGÓ: DEALS, JANUARY 2023-MAY 2026
TABLE 439 BIOGÉNESIS BAGÓ: EXPANSIONS, JANUARY 2023-MAY 2026
TABLE 440 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
TABLE 441 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
TABLE 442 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: COMPANY OVERVIEW
TABLE 443 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: PRODUCTS OFFERED
TABLE 444 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023-MAY 2026
TABLE 445 JINYU BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
TABLE 446 JINYU BIOTECHNOLOGY CO., LTD.: PRODUCTS OFFERED
TABLE 447 JINYU BIOTECHNOLOGY CO., LTD.: PRODUCT APPROVALS, JANUARY 2023-MAY 2026
TABLE 448 VAXXINOVA INTERNATIONAL B.V.: COMPANY OVERVIEW
TABLE 449 VAXXINOVA INTERNATIONAL B.V.: PRODUCTS OFFERED
TABLE 450 VAXXINOVA INTERNATIONAL B.V.: PRODUCT APPROVALS, JANUARY 2023-MAY 2026
TABLE 451 VAXXINOVA INTERNATIONAL B.V.: DEALS, JANUARY 2023-MAY 2026
TABLE 452 VAXXINOVA INTERNATIONAL B.V.: EXPANSIONS, JANUARY 2023-MAY 2026
TABLE 453 ENDOVAC ANIMAL HEALTH REBRAND CA: COMPANY OVERVIEW
TABLE 454 BRILLIANT BIO PHARMA PRIVATE LIMITED: COMPANY OVERVIEW
TABLE 455 APTIMMUNE: COMPANY OVERVIEW
TABLE 456 INDIAN IMMUNOLOGICALS LTD.: COMPANY OVERVIEW
TABLE 457 TORIGEN: COMPANY OVERVIEW
TABLE 458 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
TABLE 459 OUROFINO S.A: COMPANY OVERVIEW
TABLE 460 BIOVAC LTD.: COMPANY OVERVIEW
TABLE 461 LABORATOIRE LCV.: COMPANY OVERVIEW
TABLE 462 KYORITSU SEIYAKU CORPORATION.: COMPANY OVERVIEW
TABLE 463 STUDY ASSUMPTIONS
TABLE 464 VETERINARY VACCINES MARKET: RISK ASSESSMENT ANALYSIS

FIGURE 1 VETERINARY VACCINES MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 MARKET SCENARIO
FIGURE 3 GLOBAL VETERINARY VACCINES MARKET, 2024-2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS VETERINARY VACCINES MARKET, 2024-2026
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VETERINARY VACCINES MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS IN VETERINARY VACCINES MARKET, 2026-2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN VETERINARY VACCINES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8 RISING COMPANION ANIMAL OWNERSHIP TO DRIVE MARKET GROWTH
FIGURE 9 VETERINARY HOSPITALS SEGMENT IN ASIA PACIFIC REGION ACCOUNTED FOR LARGEST SHARE IN 2025
FIGURE 10 INDIA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 11 VETERINARY VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 12 US: PET OWNERSHIP, BY TYPE, 2024-2025 (MILLION)
FIGURE 13 US: PET INDUSTRY EXPENDITURE, 2016-2025 (USD BILLION)
FIGURE 14 VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 VETERINARY VACCINES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 16 VETERINARY VACCINES MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 VETERINARY VACCINES MARKET ECOSYSTEM
FIGURE 18 AVERAGE SELLING PRICE OF VETERINARY VACCINES, BY KEY PLAYER, 2025 (USD)
FIGURE 19 AVERAGE SELLING PRICE OF CANINE VACCINES, BY REGION, 2025 (USD)
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 21 INVESTMENT & FUNDING SCENARIO
FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR VETERINARY VACCINES PATENTS, JANUARY 2015-MAY 2026
FIGURE 23 VETERINARY VACCINES MARKET: AI USE CASES
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VETERINARY VACCINES
FIGURE 25 KEY BUYING CRITERIA FOR VETERINARY VACCINES, BY END USER
FIGURE 26 NORTH AMERICA: VETERINARY VACCINES MARKET SNAPSHOT
FIGURE 27 ASIA PACIFIC: VETERINARY VACCINES MARKET SNAPSHOT
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY VACCINES MARKET, 2023-2025
FIGURE 29 GLOBAL MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY VACCINES MARKET, 2025
FIGURE 30 VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 31 VETERINARY VACCINES MARKET: COMPANY FOOTPRINT
FIGURE 32 VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 33 EV/EBITDA OF KEY VENDORS FOR VETERINARY VACCINES
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR VETERINARY VACCINES
FIGURE 35 VETERINARY VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 36 MERCK & CO., INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2025)
FIGURE 38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025)
FIGURE 39 ELANCO: COMPANY SNAPSHOT (2025)
FIGURE 40 VIRBAC: COMPANY SNAPSHOT (2025)
FIGURE 41 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 42 HESTER BIOSCIENCS LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 43 NEOGEN CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 44 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 45 VETERINARY VACCINE MARKET: RESEARCH DESIGN
FIGURE 46 PRIMARY SOURCES
FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 49 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS
FIGURE 50 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 51 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
FIGURE 52 REVENUE SHARE ANALYSIS ILLUSTRATION: MERCK & CO., INC. (2025)
FIGURE 53 BOTTOM-UP APPROACH
FIGURE 54 TOP-DOWN APPROACH
FIGURE 55 DEMAND-SIDE APPROACH
FIGURE 56 VETERINARY VACCINES MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026-2031)
FIGURE 57 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
FIGURE 58 MARKET DATA TRIANGULATION METHODOLOGY